The average woman gains around 12 pounds across the menopause transition
March 2025 Novo Nordisk announced a 2 billion expansion of its GLP-1 manufacturing facilities in Denmark and the U.S., aiming to triple production capacity for Ozempic and Wegovy by 2027
The Phase 3 TRIUMPH program will determine whether, and at what doses, retatrutide reaches the market
Drugs able to activate a number of receptors seem to perform better
[DOI] [PubMed] [Google Scholar] 16.Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al
Pharmaceutical companies already at the forefront of GLP-1RA development have benefitted from this, while others are making significant investments to enter the weight-loss drugs market